Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Kantor

Neurology Coconut Creek, FL Medical Doctor

NPI 1881637858 CMS profile 39568

4851 W Hillsboro Blvd Ste A1, Coconut Creek, FL 33073

Open in the dashboard

General payments

$230,440

203 records reported · program years 2019–2025

Research payments

$16,552

Paid to them · 24 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$769,527 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Daniel Kantor of Coconut Creek, FL is reported in the CMS Open Payments database as having received $230,440 across 203 general payments and $16,552 in research payments paid to them. Separately, studies naming them as principal investigator received $769,527 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $150 1
2024 General $8,011 13
2023 General $1,994 12
2022 General $24,514 22
2021 General $46,995 56
2021 Research $1,250 1
2020 General $23,768 22
2020 Research $2,988 5
2019 General $125,009 77
2019 Research $12,314 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Kantor
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Daniel Kantor were reported at $150. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Daniel Kantor Neurology median Middle half National median
2019 $125,009 $474 $118–$2,177 $163
2020 $23,768 $367 $82–$2,309 $114
2021 $46,995 $438 $104–$2,547 $132
2022 $24,514 $442 $103–$2,388 $149
2023 $1,994 $464 $119–$2,312 $160
2024 $8,011 $468 $119–$2,323 $164
2025 $150 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $49,379 64 payments
  2. Avanir Pharmaceuticals, Inc. $48,304 27 payments
  3. Celgene Corporation $41,692 23 payments
  4. E.R. Squibb & Sons, L.L.C. $13,589 9 payments
  5. Genzyme Corporation $13,501 11 payments
  6. EMD Serono, Inc. $12,466 8 payments
  7. Mylan Specialty L.P. $11,029 18 payments
  8. Novartis Pharmaceuticals Corporation $9,636 5 payments
  9. Sandoz Inc. $8,061 6 payments
  10. AbbVie, Inc. $6,569 4 payments
  11. Other $16,215 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $126,699 66 payments
  2. Consulting Fee $79,671 29 payments
  3. Travel and Lodging $20,224 51 payments
  4. Food and Beverage $3,846 57 payments
Products named General payments · program years 2019–2025
  1. NUEDEXTA $48,304 27 payments
  2. ZEPOSIA $30,805 29 payments
  3. Ozanimod $24,476 3 payments
  4. AUBAGIO $13,501 11 payments
  5. Mavenclad Neurology $11,166 7 payments
  6. GILENYA $9,636 5 payments
  7. Ponvory $8,770 11 payments
  8. Epidiolex $6,407 8 payments
  9. GLATOPA $4,150 5 payments
  10. Mavenclad Neurology $1,300 1 payment
  11. Other $1,155 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $8,185 6 payments
  2. Genzyme Corporation $4,401 12 payments
  3. F. Hoffmann-La Roche AG $2,960 4 payments
  4. Sanofi-Aventis U.S. LLC $1,005 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Psychiatry & Neurology: 100

Drug cost

$92

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Phenobarbital Generic 12 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PONVORY
  • Vanda Pharmaceuticals Inc. $40
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record